Year: 2025

United States Data Center Construction Market Report 2025-2034 | Hyperscale Growth and Cloud Giants AWS, Google Cloud, and Microsoft Azure Fuel Developments – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "United States Data Center Construction Market Report and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering. The...

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded...

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis...

Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

Illustrative image Laboratory, Boehringer Ingelheim This press release is not intended for UK and US media.  HERNEXEOS® (zongertinib tablets) has been...

Anavar For Women And Men: CrazyBulk Launch Anavar Legal Steroid Alternative For Female Read Dosage, Side Effects, (Before and After Cycle results)

Anavar is a potent anabolic steroid Alternative Pills for men and women that is popular among bodybuilders and athletes in...

Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress

– Poster presentation highlights the consistency of reductions in high-sensitivity C-reactive protein with pacibekitug across clinically-meaningful subgroups – – Pacibekitug demonstrated...

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025

Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with More than 200 Participants 93% of MyClimb...

error: Content is protected !!